GLP-1 receptor agonists are the most significant advance in medical weight loss in decades. They work by mimicking glucagon-like peptide-1 — a hormone naturally produced in your gut that signals fullness to your brain, slows gastric emptying, and improves insulin response. In patients with overweight or obesity, the GLP-1 signaling system is often dysregulated: hunger feels constant, fullness feels temporary, and the underlying metabolic machinery is calibrated against weight loss.
GLP-1 medications restore the signaling. Patients describe the effect consistently — appetite quiets, "food noise" diminishes, the constant background pull toward eating fades. Combined with a normal caloric intake, this produces sustained weight loss for most patients. Clinical trials have shown 15-22% body weight loss in well-selected patients on appropriate doses, with significant improvements in cardiovascular markers, blood pressure, blood sugar, and inflammatory markers along the way.
This is the most evidence-supported pharmaceutical intervention currently available for weight management — backed by trials with tens of thousands of patients, multiple FDA approvals across both diabetes and weight-loss indications, and continually expanding evidence on downstream cardiovascular and metabolic benefits. It's also the most appropriately-prescribed-and-misprescribed weight-loss medication of the modern era, depending entirely on who's doing the prescribing.
Both work on the GLP-1 pathway. Tirzepatide adds a second mechanism (GIP receptor agonism) that produces stronger weight loss in clinical trials. The right choice depends on your situation.
The original GLP-1 medication for weight loss. Once-weekly subcutaneous injection. Clinical trials have shown roughly 15% body weight loss at the typical dose. Widely studied, well-understood side-effect profile, and the longest track record in the GLP-1 space.
Often the preferred starting point — particularly for patients sensitive to medications, those with significant GI side effects on prior medications, or those whose insurance covers semaglutide but not tirzepatide.
The newer dual-mechanism medication — combining GLP-1 receptor agonism with GIP (glucose-dependent insulinotropic polypeptide) receptor agonism. Clinical trials have shown roughly 20-22% body weight loss — meaningfully more than semaglutide for most patients.
Often the preferred choice when maximum weight-loss effect matters and the patient tolerates GLP-1 medications well. Generally a stronger appetite-suppression effect. Slightly higher cost and somewhat more potential for GI side effects, though most patients tolerate it well.
The GLP-1 telehealth boom has produced thousands of clinics that operate the same way: a quick form, a 10-minute video call, and the prescription gets shipped. Convenient, but the lack of real medical oversight has consequences — patients miss diagnoses that explain their weight, side effects don't get properly managed, plateaus aren't addressed, and discontinuation produces rapid rebound because the underlying drivers were never addressed.
Holistic Solutions operates differently. Here's the substantive comparison:
Book a free consultation. Dr. Dubroff will tell you whether GLP-1 is the right tool for your case — and what an actual physician-led program looks like compared to the alternatives.